Elevated expression of pancreatic adenocarcinoma upregulated factor (PAUF) is associated with poor prognosis and chemoresistance in epithelial ovarian cancer

被引:11
作者
Choi, Chel Hun [1 ,5 ]
Kang, Tae Heung [2 ]
Song, Joon Seon [1 ,6 ]
Kim, Young Seob [2 ]
Chung, Eun Joo [3 ]
Ylaya, Kris [1 ]
Kim, Seokho [7 ]
Koh, Sang Seok [8 ]
Chung, Joon-Yong [1 ]
Kim, Jae-Hoon [4 ]
Hewitt, Stephen M. [1 ]
机构
[1] NCI, Expt Pathol Lab, Lab Pathol, Ctr Canc Res,NIH, Bethesda, MD 20892 USA
[2] Konkuk Univ, Dept Immunol, Coll Med, Chungju 27478, South Korea
[3] NCI, Radiat Oncol Branch, Ctr Canc Res, NIH, Bldg 10, Bethesda, MD 20892 USA
[4] Yonsei Univ, Gangnam Severance Hosp, Dept Obstet & Gynecol, Coll Med, Seoul, South Korea
[5] Sungkyunkwan Univ, Dept Obstet & Gynecol, Samsung Med Ctr, Sch Med, Seoul 06351, South Korea
[6] Univ Ulsan, Dept Pathol, Asan Med Ctr, Coll Med, Seoul 05505, South Korea
[7] Korea Res Inst Biosci & Biotechnol, Aging Res Inst, Daejeon 34141, South Korea
[8] Dong A Univ, Dept Biol Sci, Busan 49315, South Korea
来源
SCIENTIFIC REPORTS | 2018年 / 8卷
基金
美国国家卫生研究院;
关键词
TOLL-LIKE RECEPTORS; CELLS; INFLAMMATION; METASTASIS; MECHANISMS; RESISTANCE; CYTOKINES; SURVIVAL; PROTEIN;
D O I
10.1038/s41598-018-30582-8
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Pancreatic adenocarcinoma upregulated factor (PAUF) is a ligand of toll-like receptors (TLRs) and has been reported to be involved in pancreatic tumor development. However, the significance of PAUF expression in epithelial ovarian cancer remains unclear. We aimed to investigate the possible clinical significance of PAUF in epithelial ovarian cancer. We examined the link between PAUF and TLR4 in ovarian cancer cell lines. Recombinant PAUF induced cell activation and proliferation in ovarian cancer cell lines, whereas PAUF knockdown inhibited these properties. Subsequently, we assessed PAUF and TLR4 expression by immunohistochemistry on tissue microarray of 408 ovarian samples ranging from normal to metastatic. PAUF expression positively correlated with TLR4 expression. Overexpression of PAUF was associated with high-grade tumor (p = 0.014) and chemoresistant tumor (p = 0.017). Similarly, high expression of TLR4 correlated with advanced tumor stage (p = 0.002) and chemoresistant tumor (p = 0.001). Multivariate analysis indicated that PAUF(high), TLR4(high), and PAUF(high)/TLR4(high) expression are independent prognostic factor for progression-free survival, while TLR4(high) and PAUF(high)/TLR4(high) expression were independent prognostic factors for overall survival. Our results suggest that PAUF has a role in ovarian cancer progression and is a potential prognostic marker and novel chemotherapeutic target for ovarian cancer.
引用
收藏
页数:11
相关论文
共 40 条
  • [1] A cytokine profile of normal and malignant ovary
    Burke, F
    Relf, M
    Negus, R
    Balkwill, F
    [J]. CYTOKINE, 1996, 8 (07) : 578 - 585
  • [2] Cancers take their Toll - the function and regulation of Toll-like receptors in cancer cells
    Chen, R.
    Alvero, A. B.
    Silasi, D-A
    Steffensen, K. D.
    Mor, G.
    [J]. ONCOGENE, 2008, 27 (02) : 225 - 233
  • [3] Inflammation, cancer and chemoresistance: Taking advantage of the toll-like receptor signaling pathway
    Chen, Rui
    Alvero, Ayesha B.
    Silasi, Dan-Arin
    Mor, Gil
    [J]. AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2007, 57 (02) : 93 - 107
  • [4] Expression of fibroblast growth factor receptor family members is associated with prognosis in early stage cervical cancer patients
    Choi, Chel Hun
    Chung, Joon-Yong
    Kim, Jae-Hoon
    Kim, Byoung-Gie
    Hewitt, Stephen M.
    [J]. JOURNAL OF TRANSLATIONAL MEDICINE, 2016, 14 : 1 - 12
  • [5] Pancreatic adenocarcinoma up-regulated factor expression is associated with disease-specific survival in cervical cancer patients
    Choi, Chel Hun
    Chung, Joan-Yang
    Park, Ho-Seop
    Jun, Minsik
    Lee, Yoo-Young
    Kim, Byung-Gie
    Hewitt, Stephen M.
    [J]. HUMAN PATHOLOGY, 2015, 46 (06) : 884 - 893
  • [6] Circulating Inflammation Markers and Risk of Epithelial Ovarian Cancer
    Clendenen, Tess V.
    Lundin, Eva
    Zeleniuch-Jacquotte, Anne
    Koenig, Karen L.
    Berrino, Franco
    Lukanova, Annekatrin
    Lokshin, Anna E.
    Idahl, Annika
    Ohlson, Nina
    Hallmans, Goran
    Krogh, Vittorio
    Sieri, Sabina
    Muti, Paola
    Marrangoni, Adele
    Nolen, Brian M.
    Liu, Mengling
    Shore, Roy E.
    Arslan, Alan A.
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2011, 20 (05) : 799 - 810
  • [7] Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes
    Cubillos-Ruiz, Juan R.
    Rutkowski, Melanie
    Conejo-Garcia, Jose R.
    [J]. CELL CYCLE, 2010, 9 (02) : 260 - 268
  • [8] Immune cells as mediators of solid tumor metastasis
    DeNardo, David G.
    Johansson, Magnus
    Coussens, Lisa M.
    [J]. CANCER AND METASTASIS REVIEWS, 2008, 27 (01) : 11 - 18
  • [9] A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer
    du Bois, A
    Lück, HJ
    Meier, W
    Adams, HP
    Möbus, V
    Costa, S
    Bauknecht, T
    Richter, B
    Warm, M
    Schröder, W
    Olbricht, S
    Nitz, U
    Jackisch, C
    Emons, G
    Wagner, U
    Kuhn, W
    Pfisterer, J
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (17): : 1320 - 1330
  • [10] Eltabbakh G H, 2001, Expert Opin Pharmacother, V2, P109, DOI 10.1517/14656566.2.1.109